The ADAPTMET project finds a strategic stronghold in Belgium through the leadership of Professor Cédric Blanpain, a world-renowned physician-scientist at the Université Libre de Bruxelles (ULB) and CEO of Cancer State Therapeutics. This dual role perfectly embodies the project’s mission: translating fundamental discovery into clinical impact. By focusing on the mechanisms of metastasis, responsible for over 90% of cancer deaths, Professor Blanpain’s teams at both the university and his biotech firm are working to identify new therapeutic targets. Supported by the European Union’s Marie Skłodowska-Curie Actions, this Walloon success story not only advances our understanding of cancer cell adaptation but also trains the next generation of researchers at the intersection of academia and industry, ensuring that scientific breakthroughs reach patients faster.

Read more on the NCP Wallonie webiste.